Portola Pharmaceuticals, Inc. Announces New Phase 2 Results Confirming Immediate, Dose-Dependent And Well-Tolerated Reversal Of Anticoagulation Activity Of XARELTO® (Rivaroxaban) With Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Reversal

Published: Dec 10, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced additional results of a Phase 2 proof-of-concept study that showed andexanet alfa's ability to immediately reverse the anticoagulation activity of XARELTO® (rivaroxaban) through the administration of a short intravenous bolus. The data also showed that this reversal can be prolonged if needed by a continuous infusion. Andexanet alfa was well tolerated, with no serious adverse events reported. The data were presented at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans by lead investigator Mark Crowther, M.D., M.Sc., associate chair, Department of Medicine, McMaster University, Hamilton, Ontario.

Help employers find you! Check out all the jobs and post your resume.

Back to news